-
2024-511880-27-00
4
Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radio
-
2024-514144-85-02
3
Glioblastoma
-
2024-514244-81-00
5
Uncomplicated candidemia
-
2024-515340-23-00
4
Colon cancer
-
2024-516115-24-00
9
High risk relapsed neuroblastoma (relapsed or progressed after being d
-
2024-518251-31-00
5
patients hospitalized for a septic shock with hypercontractlity
-
2024-519003-99-00
4
Hidrdenitis suppurative
-
2024-519246-75-01
4
Patients With Muscle-Invasive Bladder Cancer
-
2024-520294-13-00
1
Cutaneous T-cell lymphomas (CTCL)
-
2025-521221-32-00
5
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2025-521290-14-00
5
Surgery with sternotomy
-
2025-522855-25-00
5
Carcinoma, Transitional Cell
-
2025-523539-20-00
4
Low Grade Upper Tract Urothelial Carcinoma
-
2025-524367-20-00
4
Adult patients with primary mitochondrial disease
-
2025-522996-27-00
5
2026-05-05
recurrent and/or metastatic squamous cell carcinoma of the head and ne
-
2023-505661-89-00
4
2025-12-19
Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma
-
2025-521775-31-00
5
2025-11-12
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
-
2024-520107-12-00
5
2025-09-03
Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
-
2024-517589-41-00
1
2025-08-04
Advanced solid tumors
-
2024-519132-17-00
4
2025-01-29
NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA
-
2024-517410-15-01
5
2025-01-14
Rectal cancer
-
2024-514135-17-00
5
2024-11-28
Immunoglobulin A Nephropathy
-
2024-519113-59-00
4
2024-11-20
Hepatocellular carcinoma